Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

MLA

Brandt, J. T., et al. “Common Polymorphisms of CYP2C19 and CYP2C9 Affect the Pharmacokinetic and Pharmacodynamic Response to Clopidogrel but Not Prasugrel.” Journal of Thrombosis and Haemostasis : JTH, vol. 5, no. 12, Dec. 2007, pp. 2429–36. EBSCOhost, https://doi.org/10.1111/j.1538-7836.2007.02775.x.

APA

Brandt, J. T., Close, S. L., Iturria, S. J., Payne, C. D., Farid, N. A., Ernest, C. S., 2nd, Lachno, D. R., Salazar, D., & Winters, K. J. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis : JTH, 5(12), 2429–2436. https://doi.org/10.1111/j.1538-7836.2007.02775.x

Chicago

Brandt, J T, S L Close, S J Iturria, C D Payne, N A Farid, C S Ernest 2nd, D R Lachno, D Salazar, and K J Winters. 2007. “Common Polymorphisms of CYP2C19 and CYP2C9 Affect the Pharmacokinetic and Pharmacodynamic Response to Clopidogrel but Not Prasugrel.” Journal of Thrombosis and Haemostasis : JTH 5 (12): 2429–36. doi:10.1111/j.1538-7836.2007.02775.x.